Nicholas J. Vogelzang

Nicholas J. Vogelzang, M.D.
Born (1949-12-13) December 13, 1949
Holland, Michigan
Alma mater University of Illinois School of Medicine
Occupation Oncologist
Employer Comprehensive Cancer Centers of Nevada
Known for Cancer research
Board member of Chair and medical director of the Developmental Therapeutics Committee and co-chair of the Genitourinary Committee for U.S. Oncology Research

Nicholas J. Vogelzang is a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

Career

Vogelzang joined Comprehensive Cancer Centers of Nevada in 2009 as a medical oncologist and serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research.[1] Since 2004, he has been Head of the Genitourinary Oncology and Clinical Professor of Medicine for the University of Nevada School of Medicine in Las Vegas and Reno, Nevada.

He served as Director, Executive Vice President for Academic Affairs and Professor at Nevada Cancer Institute (NVCI) from 2004 to 2009.

During his tenure at the University of Chicago, he served as Professor of Medicine and Surgery (Urology) (1993 to 2003), Director for the University of Chicago Cancer Research Center (1999–2003), and was named the first Fred C. Buffett Professor in Medicine and Chair in Genitourinary Oncology (1999–2003).[2]

Vogelzang received his M.D. from the University of Illinois at Chicago in 1974. He completed his internship, residency and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. Vogelzang became the first editor of the Textbook of Genitourinary Oncology and remains the lead editor today.

Research

In 2002, Vogelzang directed the largest Phase II trial for mesothelioma using pemetrexed (brand name Alimta, by Eli Lilly). Pemetrexed is an antifolate, a class of drugs that targets the folic acid metabolic pathway. The results of the trial showed tumors shrank in 41 percent of patients on pemetrexed in combination with a more commonly used chemotherapy agent called cisplatin. Only 17 percent of patients receiving cisplatin alone experienced tumor shrinkage. Additionally, those on the pemetrexed combination lived nearly three months longer than those on cisplatin alone.[3][4]

Active research support

Vogelzang is actively involved in many research studies to test new therapies and treatments including:

Professional memberships

Vogelzang served on committees for the American Society of Clinical Oncology (ASCO), as well as its board of directors from 1993 to 1996, and is a former president of the Illinois Division of the American Cancer Society. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, and chair of the CALGB Prostate Committee from 1993 to 1999.

He is a founding board member of the Mesothelioma Applied Research Foundation (MARF) and a member the American Association for Cancer Research, the American Urological Association, the Society of Urologic Oncology and the European Society for Medical Oncology. Vogelzang is the 2012 Chair for the American Society of Clinical Oncology's (ASCO) Cancer Communications Committee, the current Vice Chair of the GU Committee and a member of the GU Translational Medicine Intergroup Committee for Southwest Oncology Group. For more than ten years, Vogelzang has served on the Medical and Scientific Advisory Boards for Us TOO, a prostate cancer education and support network for persons affected by prostate cancer.

Vogelzang is also a current or past member of several medical societies including:

Corporate relationships

Vogelzang is a corporate consultant for the following companies: Aveo Pharmaceuticals Inc., Celgene Corporation, Dendreon, Exelixis Inc., Novartis AG, OncoGeneX/Teva Pharmaceutical Industries Ltd., Veridex, and Viamet.

He is also a member of the speakers' bureaus for Caris Life Sciences, Dendreon, Eli Lilly and Company, Inc., Novartis AG, and Sanofi-Aventis U.S.

Published works

In the media

Awards and Honors

Vogelzang has been recognized for his work by many of the leading medical groups and research organizations in the United States. Some of his notable honors include:

References

  1. ↑ http://www.cccnevada.com/our-physicians/medical-oncologists/dr-nicholas-vogelzang-m-d/
  2. ↑ http://chronicle.uchicago.edu/990715/vogelzang.shtml
  3. ↑ http://www.mesotheliomaweb.org/pemetrexed.htm
  4. ↑ http://www.ALIMTA.com
  5. ↑ http://health.usnews.com/doctors/nicholas-vogelzang-9621
  6. ↑ http://jco.ascopubs.org/content/31/1/131.long
  7. ↑ "Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.". Eur Urol. 63 (4): 717–23. Apr 2013. doi:10.1016/j.eururo.2012.11.042. PMID 23206856.
  8. ↑ http://jco.ascopubs.org/content/early/2012/11/16/JCO.2012.45.0494.full.pdf
  9. ↑ http://www.biomedexperts.com/Abstract.bme/23435622/A_randomized_double-blind_placebo-controlled_Phase_II_study_with_and_without_enzastaurin_in_combination_with_docetaxe
  10. ↑ http://meetinglibrary.asco.org/content/107247-134
  11. ↑ "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.". Lancet Oncol. 13 (10): 983–92. Oct 2012. doi:10.1016/S1470-2045(12)70379-0. PMID 22995653.
  12. ↑ "Everolimus vs. Temsirolimus for Advanced Renal Cell Carcinoma: Use and Use of Resources in the US Oncology Network". Clinical Genitourinary Cancer. 11: 115–120. doi:10.1016/j.clgc.2012.09.008.
  13. ↑ "A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.". Clin Genitourin Cancer. 12 (3): 167–177.e2. Jun 2014. doi:10.1016/j.clgc.2013.11.007. PMID 24365125.
  14. ↑ http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470204512704291.pdf
  15. ↑ http://jco.ascopubs.org/content/30/20/2509.full
  16. ↑ http://jco.ascopubs.org/content/29/15/2040.long
  17. ↑ http://jco.ascopubs.org/content/early/2011/05/06/JCO.2011.34.8433.abstract
  18. ↑ "Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.". Urology. 77 (5): 1172–6. May 2011. doi:10.1016/j.urology.2010.12.043. PMID 21334731.
  19. ↑ "Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.". Clin Cancer Res. 17 (10): 3431–42. May 2011. doi:10.1158/1078-0432.CCR-10-2345. PMID 21220472.
  20. ↑ http://jco.ascopubs.org/content/29/15/2040.long
  21. ↑ http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09970.x/abstract
  22. ↑ http://vegasseven.com/top-docs-2014/medical-oncology/
  23. ↑ http://www.desertcompanion.com/article.cfm?ArticleID=186
  24. ↑ http://www.reviewjournal.com/news/las-vegas/fire-captain-other-everyday-heroes-honored-american-red-cross
  25. ↑ http://health.usnews.com/doctors/nicholas-vogelzang-9621
This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.